[go: up one dir, main page]

MX9700340A - Agentes anti-helicobacter derivados sulfonamida de azolonas. - Google Patents

Agentes anti-helicobacter derivados sulfonamida de azolonas.

Info

Publication number
MX9700340A
MX9700340A MX9700340A MX9700340A MX9700340A MX 9700340 A MX9700340 A MX 9700340A MX 9700340 A MX9700340 A MX 9700340A MX 9700340 A MX9700340 A MX 9700340A MX 9700340 A MX9700340 A MX 9700340A
Authority
MX
Mexico
Prior art keywords
4alkyl
azolonas
compounds
sulfonamide derivative
derivative anti
Prior art date
Application number
MX9700340A
Other languages
English (en)
Inventor
Jan Heeres
Raymond Antoine Stokbroekx
Joseph Hector Mostmans
Louis Jozef Elizabeth Va Veken
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX9700340A publication Critical patent/MX9700340A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Lubricants (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invencion se refiere a los compuestos que tienen la formula (I), las sales de adicion farmacéuticamente aceptables y las formas estereoquímicamente isoméricas de los mismos, en donde Y es CH o N; R1, R2 y R3 son independientemente cada uno hidrogeno o alquilo de C1-4; R4 y R5 son cada uno independientemente hidrogeno, halogeno, alquilo de C1-4, alquiloxilo de C1-4, hidroxilo, trifluorometilo, trifluorometiloxi o difluorometiloxi; R6 es alquilo de C1-4; o fenilo substituido opcionalmente con halogeno, alquilcarbonilamino de C1-4, alquiloxilo de C1-4, alquilo de C1-4 o nitro; Z es C=O o CHOH; y (1) es un radical de formula (a-1), (a-2), (a-3), (a-4), (a-5), (a-6), o (a-7); composiciones que comprenden dichos compuestos, procedimientos para la preparacion de los mismos y el uso de estos compuestos como una medicina.
MX9700340A 1994-07-12 1995-07-05 Agentes anti-helicobacter derivados sulfonamida de azolonas. MX9700340A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94202015 1994-07-12
PCT/EP1995/002619 WO1996001818A1 (en) 1994-07-12 1995-07-05 Sulfonamide derivatives of azolones anti-helicobacter agents

Publications (1)

Publication Number Publication Date
MX9700340A true MX9700340A (es) 1997-05-31

Family

ID=8217029

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9700340A MX9700340A (es) 1994-07-12 1995-07-05 Agentes anti-helicobacter derivados sulfonamida de azolonas.

Country Status (21)

Country Link
US (2) US5571811A (es)
EP (1) EP0770071B1 (es)
JP (1) JPH10502386A (es)
CN (1) CN1068878C (es)
AT (1) ATE206706T1 (es)
AU (1) AU684981B2 (es)
BR (1) BR9508376A (es)
CA (1) CA2194562A1 (es)
CZ (1) CZ2997A3 (es)
DE (1) DE69523159T2 (es)
FI (1) FI970113A0 (es)
HU (1) HUT76636A (es)
IL (1) IL114537A (es)
MX (1) MX9700340A (es)
NO (1) NO970089L (es)
NZ (1) NZ289853A (es)
PL (1) PL318149A1 (es)
SK (1) SK4497A3 (es)
TW (1) TW341571B (es)
WO (1) WO1996001818A1 (es)
ZA (1) ZA955760B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639754A (en) * 1994-07-12 1997-06-17 Janssen Pharmaceutica N.V. Urea and thiourea derivatives of azolones
US5637592A (en) * 1994-07-12 1997-06-10 Janssen Pharmaceutica N.V. Acyl derivatives of azolones
US5571811A (en) * 1994-07-12 1996-11-05 Janssen Pharmaceutica N.V. Sulfonamide derivatives of azolones
DE60033019D1 (de) 1999-03-17 2007-03-08 Morinaga & Co Arzneimittel, nahrungsmittel, getränke und futter enthaltend eine kakao-komponente
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6780880B1 (en) * 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
ES2387617T3 (es) * 2002-11-14 2012-09-27 Aderans Research Institute, Inc. Cultivo de células inductoras de cabello
US8013156B2 (en) * 2003-03-19 2011-09-06 Exelixis, Inc. Tie-2 modulators and methods of use
AU2005286793A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
CN101083993A (zh) * 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
AR051095A1 (es) * 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso comoinhibidores de la estearoil-coa desaturasa
CN101084212A (zh) * 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
AR051294A1 (es) * 2004-09-20 2007-01-03 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
US7777036B2 (en) * 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
MX2007003325A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
US20220122691A1 (en) * 2019-01-06 2022-04-21 Psomagen Inc. HtrA Inhibitors and CagA Inhibitors and Use Thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1292472C (en) * 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
US4791111A (en) * 1985-12-23 1988-12-13 Janssen Pharmaceutica, N.V. [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles having anti-microbial properties
CA1331757C (en) * 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
CA2076257A1 (en) * 1991-09-13 1993-03-14 Jan Heeres 4-¬4-¬4-(4-hydroxyphenyl)-1- piperazinyl|phenyl|-5-methyl-3h -1,2,4-triazol-3-one derivatives
US5571811A (en) * 1994-07-12 1996-11-05 Janssen Pharmaceutica N.V. Sulfonamide derivatives of azolones

Also Published As

Publication number Publication date
NO970089D0 (no) 1997-01-09
CN1068878C (zh) 2001-07-25
FI970113L (fi) 1997-01-10
AU2981995A (en) 1996-02-09
DE69523159T2 (de) 2002-06-20
IL114537A (en) 1999-04-11
IL114537A0 (en) 1995-11-27
BR9508376A (pt) 1997-10-28
TW341571B (en) 1998-10-01
FI970113A7 (fi) 1997-01-10
US5728700A (en) 1998-03-17
CA2194562A1 (en) 1996-01-25
WO1996001818A1 (en) 1996-01-25
NO970089L (no) 1997-03-10
AU684981B2 (en) 1998-01-08
HU9700080D0 (en) 1997-02-28
JPH10502386A (ja) 1998-03-03
FI970113A0 (fi) 1997-01-10
PL318149A1 (en) 1997-05-12
EP0770071A1 (en) 1997-05-02
CZ2997A3 (en) 1997-09-17
DE69523159D1 (de) 2001-11-15
SK4497A3 (en) 1997-12-10
HUT76636A (en) 1997-10-28
ATE206706T1 (de) 2001-10-15
CN1152308A (zh) 1997-06-18
ZA955760B (en) 1997-01-13
NZ289853A (en) 1997-11-24
EP0770071B1 (en) 2001-10-10
US5571811A (en) 1996-11-05

Similar Documents

Publication Publication Date Title
MX9700340A (es) Agentes anti-helicobacter derivados sulfonamida de azolonas.
AR023727A1 (es) Compuestos empleados en el tratamiento de padecimientos inflamatorios
SV1999000016A (es) Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv
ES2178152T3 (es) Nuevas modificaciones de 2-amino-4-(4-fluorobenzilamino)-1-etoxicarbonilaminobenceno y procedimientos para la preparacion de dicho compuesto.
AR005706A1 (es) Inhibidores egfr de 4-aminoquinzolina, procedimiento para su obtencion, composicion farmaceutica que los contiene, uso de los mismos para lapreparacion de un medicamento util como agente antineoplasico
ES2134755T3 (es) Derivados de quinolina como antagonistas de leucotrieno d4, composiciones que contienen los mismos y procedimientos para su preparacion.
ES2031876T3 (es) Un procedimiento para la preparacion de 5,6-dihidro-2-(fenil sustituido)-1,2,4,-triazin-3,5(2h,4h)-dionas.
ES2142034T3 (es) Compuestos biaromaticos que llevan un grupo adamantilo en orto, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
AR034475A1 (es) Derivados de androstano antiinflamatorios
AR032361A1 (es) Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos
ES2075121T3 (es) Nuevos compuestos triciclicos.
AR028948A1 (es) Compuestos novedosos
ES2171884T3 (es) Compuestos de quinazolina.
PE20040411A1 (es) Compuestos de aril cetona pirrolo triazina
ES2037013T3 (es) Procedimiento para preparar tieno-1,4-diazepinas.
AR013477A1 (es) Prostaglandinas de tetrahidro sustituido c16-20 aromatico utiles como agonistas de fp.
ES2057076T3 (es) Compuestos de quinoxalina y su preparacion y empleo.
ES2119325T3 (es) Compuestos polienicos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
PA8463001A1 (es) Compuestos de eteres ciclicos de piperidinilaminometil trifluorometilo como antagonistas de la sustancia p
ES2143734T3 (es) Compuestos bioaromaticos que llevan un grupo adamantilo en para, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
MX9700338A (es) Derivados heterociclicos de azolona anti-helicobacter.
ES2089255T3 (es) N-(ariloxialquil)heteroaril-8-azabiciclo(3.2.1)octanos, compuestos intermedios y un procedimiento para su preparacion y su uso como medicamentos.
AR014146A1 (es) Compuestos de triazina, su uso en terapia, composiciones farmaceuticas que los contienen, proceso para su manufactura e intermediarios de sintesis
CL2022003067A1 (es) Derivados de n-(piperidin-4-il)benzamida de acción luminal
AR028947A1 (es) Compuestos novedosos